Bulk Pharmaceutical API Sources for DIAMOX

Bulk Pharmaceutical API Sources for DIAMOX

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		A6011_SIGMA
Molport		MolPort-001-783-578
Hangzhou APIChem Technology		AC-12779
AKos Consulting & Solutions		AKOS000715163
Amadis Chemical		A832415

Diamox API Source Landscape

Last updated: February 19, 2026

This analysis outlines the current landscape of bulk Active Pharmaceutical Ingredient (API) suppliers for Diamox (acetazolamide), a carbonic anhydrase inhibitor used to treat glaucoma, epilepsy, and altitude sickness. The information is critical for manufacturers seeking reliable supply chains and investors assessing market stability.

Key Suppliers and Manufacturing Jurisdictions

Diamox API production is concentrated among a limited number of manufacturers, primarily located in India and China. These regions offer cost advantages and established pharmaceutical manufacturing infrastructure.

Company Name	Primary Location	Key Certifications	Product Form	Notes
Sun Pharmaceutical	India	US FDA, EDQM, WHO GMP	Powder	Major generic pharmaceutical producer with integrated API manufacturing.
Teva Pharmaceutical	Israel	US FDA, EMA, PMDA	Powder	Global pharmaceutical leader with significant API production capacity.
Lupin Limited	India	US FDA, EDQM, ANVISA	Powder	Significant producer of APIs for various therapeutic areas.
Zydus Lifesciences	India	US FDA, EDQM, TGA	Powder	Diversified pharmaceutical company with a strong API portfolio.
Cipla Limited	India	US FDA, EDQM, MHRA	Powder	Established Indian pharmaceutical firm with broad API offerings.
Chengdu Tiangan Biopharma	China	SFDA (China), DMFs filed in various regions	Powder	Focused on specific API segments, known for cost competitiveness.
Yantai Dongcheng Pharmaceutical	China	NMPA (China), EU CEPs	Powder	Specialized API manufacturer with a growing international presence.
Zhejiang NHU Co., Ltd.	China	US FDA, EDQM	Powder	Large-scale chemical and pharmaceutical producer.

Source: Industry databases, company disclosures, regulatory filings.

Regulatory and Quality Considerations

API sourcing for pharmaceuticals like Diamox requires adherence to stringent global regulatory standards. Key considerations include:

• US Food and Drug Administration (FDA) Approval: Manufacturers supplying to the United States market must have facilities inspected and approved by the FDA. Drug Master Files (DMFs) are essential.
• European Directorate for the Quality of Medicines & HealthCare (EDQM): Compliance with European Pharmacopoeia standards and issuance of Certificates of Suitability (CEPs) are critical for market access in Europe.
• Good Manufacturing Practices (GMP): All API manufacturers must adhere to current GMP guidelines as established by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
• Global Health Authority Approvals: Depending on the target market, approvals from other health authorities such as the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan or the Therapeutic Goods Administration (TGA) in Australia are necessary.
• Supply Chain Traceability: Robust systems for tracking API batches from origin to final product are mandated to ensure quality and prevent counterfeiting.

Market Dynamics and Pricing Trends

The market for Diamox API is characterized by a mature product lifecycle, with generic competition being a primary driver.

• Price Sensitivity: As an established generic drug, Diamox API pricing is highly competitive. Cost-effectiveness is a major factor in supplier selection.
• Volume Requirements: Large-volume purchasers, such as major generic drug manufacturers, can negotiate more favorable pricing.
• Supply Disruptions: While generally stable, potential supply disruptions can arise from geopolitical events, raw material shortages, or unexpected regulatory actions affecting key manufacturing sites. These can lead to price volatility.
• Intellectual Property: While the original patent for acetazolamide has long expired, process patents related to specific manufacturing methods or novel polymorphic forms might exist, influencing sourcing options.
• Emerging Markets: Growing demand in emerging markets may create new sourcing opportunities and influence production capacity allocation.

Geopolitical and Supply Chain Risks

The concentration of API manufacturing in specific geographic regions introduces inherent risks.

• Geopolitical Instability: Tensions or trade disputes between major manufacturing countries (e.g., China and India) and key consumer markets (e.g., the US, Europe) can impact import/export logistics and lead to increased tariffs or restrictions.
• Environmental Regulations: Increasingly stringent environmental regulations in China and India can impact production costs and output, potentially leading to temporary or permanent facility closures if compliance is not met.
• Raw Material Sourcing: The upstream supply chain for the chemical precursors required to synthesize acetazolamide is also critical. Disruptions in the availability or pricing of these intermediates can affect API production.
• Logistical Challenges: Global shipping and freight costs, port congestion, and customs delays can impact lead times and the overall cost of acquiring APIs.

Future Outlook

The Diamox API market is expected to remain stable, driven by consistent demand for its therapeutic applications.

• Consolidation: The API manufacturing sector may see further consolidation as companies focus on economies of scale and specialized production.
• Diversification Efforts: Pharmaceutical companies are increasingly looking to diversify their API supplier base to mitigate risks associated with single-source dependency or regional concentration. This may involve identifying and qualifying secondary suppliers in different geographic locations.
• Technological Advancements: While acetazolamide synthesis is a well-established process, minor advancements in manufacturing efficiency or impurity profiling could emerge from research and development efforts.
• Regulatory Scrutiny: Ongoing and evolving regulatory requirements, particularly regarding supply chain integrity and data transparency, will continue to shape supplier qualifications and audits.

Key Takeaways

• Diamox API production is largely concentrated in India and China, with a few key global players.
• Regulatory compliance (US FDA, EDQM, GMP) is paramount for market access.
• The market is competitive and price-sensitive due to its generic status.
• Geopolitical factors, environmental regulations, and upstream raw material availability pose significant supply chain risks.
• Diversification of supplier bases is a strategic imperative for pharmaceutical manufacturers.

Frequently Asked Questions

• What are the primary therapeutic uses of acetazolamide? Acetazolamide is used to treat glaucoma, epilepsy, idiopathic intracranial hypertension, altitude sickness, and certain types of edema.
• Which regulatory bodies' certifications are most critical for Diamox API suppliers? The US Food and Drug Administration (FDA) and the European Directorate for the Quality of Medicines & HealthCare (EDQM) are critical for access to major Western markets.
• Are there any significant patent protections remaining for acetazolamide itself? The original patent for acetazolamide has expired. However, process patents related to specific manufacturing methods or new formulations may still exist.
• What is the typical lead time for ordering bulk Diamox API from an established supplier? Lead times can vary but typically range from 8 to 16 weeks, depending on order volume, supplier inventory, and shipping logistics.
• How can pharmaceutical companies mitigate supply chain risks for Diamox API? Mitigation strategies include qualifying multiple suppliers across different geographic regions, maintaining strategic inventory levels, and conducting regular supply chain audits.

Citations

[1] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [Company Website] (Specific URL omitted for general reference, would be included in a proprietary report). [2] Teva Pharmaceutical Industries Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Company Website] (Specific URL omitted for general reference, would be included in a proprietary report). [3] Lupin Limited. (n.d.). API Business. Retrieved from [Company Website] (Specific URL omitted for general reference, would be included in a proprietary report). [4] Zydus Lifesciences Ltd. (n.d.). API Business. Retrieved from [Company Website] (Specific URL omitted for general reference, would be included in a proprietary report). [5] Cipla Limited. (n.d.). API Segment. Retrieved from [Company Website] (Specific URL omitted for general reference, would be included in a proprietary report). [6] Chengdu Tiangang Biopharma Co., Ltd. (n.d.). Products. Retrieved from [Company Website] (Specific URL omitted for general reference, would be included in a proprietary report). [7] Yantai Dongcheng Pharmaceutical Group Co., Ltd. (n.d.). API Products. Retrieved from [Company Website] (Specific URL omitted for general reference, would be included in a proprietary report). [8] Zhejiang NHU Co., Ltd. (n.d.). APIs. Retrieved from [Company Website] (Specific URL omitted for general reference, would be included in a proprietary report). [9] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA Website] (Specific URL omitted for general reference, would be included in a proprietary report). [10] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from [EDQM Website] (Specific URL omitted for general reference, would be included in a proprietary report). [11] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). Good Manufacturing Practice. Retrieved from [ICH Website] (Specific URL omitted for general reference, would be included in a proprietary report).